TAXUS ATLAS: TAXUS Liberté™-SR Stent for the Treatment of de Novo Coronary Artery Lesions

General Inclusion Criteria:

1. Patient is ≥18 years old.

2. Eligible for percutaneous coronary intervention (PCI)

3. Documented stable angina pectoris or unstable angina pectoris with documented ischemiaor documented silent ischemia

4. Left ventricular ejection fraction (LVEF) of >/=25%

5. Acceptable candidate for coronary artery bypass grafting (CABG)

6. Patient or legal guardian understands the study requirements and the treatmentprocedures and provides written Informed Consent before any study-specific tests orprocedures are performed

7. Willing to comply with all specified follow-up evaluations Angiographic Inclusion Criteria:

8. Only one lesion (target lesion) may be treated with the study stent. However, oneadditional lesion in a non-target vessel may be treated during the index procedurewith a commercially available bare metal stent, heparin-coated stent or TAXUS Expressstent.

9. Target lesion enrolled for treatment may be composed of multiple lesions (not morethan 10mm between diseased segments)but must be completely covered by one study stent.

10. Target lesion located within a single native coronary artery

11. Cumulative target lesion length is ≥10 mm and ≤28 mm (visual estimate)

12. RVD of ≥2.5 mm to ≤4.0 mm (visual estimate)

13. Target lesion diameter stenosis ≥50% (visual estimate)

14. Target lesion is de novo (i.e., a coronary lesion not previously treated)

General Exclusion Criteria:

1. Known hypersensitivity to paclitaxel

2. Any previous, concurrent or planned treatment with a non-study anti-restenoticdrug-coated or drug-eluting coronary stent.

3. Previous or planned use of both the study stent and a non-study stent (i.e.,commercial stent) in the treatment of the target vessel

4. Previous or planned treatment with intravascular brachytherapy in the target vessel

5. Planned CABG ≤9-months post-index procedure

6. MI within 72 hours prior to the index procedure and or creatine kinase(CK) >2x thelocal laboratory's ULN unless CK-MB is <2x ULN.

7. Cerebrovascular Accident (CVA) within the past 6 months

8. Cardiogenic Shock

9. Acute or chronic renal dysfunction

10. Contraindication to ASA, or to both clopidogrel and ticlopidine

11. Leukopenia

12. Thrombocytopenia or thrombocytosis

13. Active peptic ulcer or active gastrointestinal (GI) bleeding

14. Known allergy to stainless steel

15. Any prior true anaphylactic reaction to contrast agents

16. Patient is currently, or has been treated with paclitaxel or other chemotherapeuticagents within 12-months of the index procedure

17. Anticipated treatment with paclitaxel or oral rapamycin during any period in the 9-months after the index procedure

18. Male or female with known intention to procreate within 3 months after the indexprocedure

19. Female of childbearing potential with a positive pregnancy test within 7 days beforethe index procedure, or lactating, or intends to become pregnant during the study.

20. Life expectancy of less than 24-months due to other medical condition

21. Co-morbid condition(s) that could limit the patient's ability to participate in thestudy, compliance with follow-up requirements or impact the scientific integrity ofthe study

22. Currently participating in another investigational drug or device study that has notcompleted the primary endpoint or that clinically interferes with the endpoints ofthis study. Angiographic Exclusion Criteria:

23. Left main coronary artery disease (stenosis >50%) whether protected or unprotected

24. Target lesion is ostial in location (within 3.0 mm of vessel origin)

25. Target lesion and/or target vessel proximal to the target lesion is moderately orseverely calcified by visual estimate.

26. Target lesion and/or target vessel proximal to the target lesion is tortuous.

27. Target lesion is located within or distal to a >60 degree bend in the vessel

28. Target lesion involves a bifurcation with a side branch vessel >2.0 mm in diameter.

29. Target lesion is totally occluded (TIMI flow </= 1), either at baseline or predilation

30. Angiographic presence of probable or definite thrombus

31. Pre-treatment of the target vessel is not allowed with any device